(Q36206632)

12 August 2017

1 reference

retracted paper

2 references

Dataset for "Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine"

Continued use of retracted papers: Temporal trends in citations and (lack of) awareness of retractions shown in citation contexts in biomedicine

title

Therapy targeted at vascular endothelial growth factor in metastatic renal cell carcinoma: biology, clinical results and future development (English)

1 reference

metastatic renal cell carcinoma

12 August 2017

0 references

1 reference

1 reference

3

Robert J Motzer

1 reference

12 August 2017

Brian I Rini

1

1 reference

12 August 2017

Jeffrey A Sosman

series ordinal

2

1 reference

12 August 2017

publication date

1 August 2005

1 reference

12 August 2017

1 reference

12 August 2017

volume

96

1 reference

12 August 2017

issue

3

1 reference

12 August 2017

page(s)

286-290

1 reference

The biology of vascular endothelial growth factor

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05616.X

Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) delays and induces escape from senescence in human dermal microvascular endothelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05616.X

Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05616.X

The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05616.X

Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05616.X

Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05616.X

Post-transcriptional regulation of vascular endothelial growth factor mRNA by the product of the VHL tumor suppressor gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05616.X

A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05616.X

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05616.X

Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05616.X

Phase II trial of antiepidermal growth factor receptor antibody C225 in patients with advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05616.X

Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05616.X

Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1464-410X.2005.05616.X

Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells

21 January 2018

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1111/J.1464-410X.2005.05616.X

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1111/J.1464-410X.2005.05616.X

Tumor suppression and transcription elongation: the dire consequences of changing partners

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1111/J.1464-410X.2005.05616.X

Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1111/J.1464-410X.2005.05616.X

Binding of the von Hippel-Lindau tumor suppressor protein to Elongin B and C

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1111/J.1464-410X.2005.05616.X

Identification of the von Hippel-Lindau disease tumor suppressor gene

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1111/J.1464-410X.2005.05616.X

Oxygen tension regulates the expression of the platelet-derived growth factor-B chain gene in human endothelial cells

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1111/J.1464-410X.2005.05616.X

Cancer and Leukemia Group B 90206: A randomized phase III trial of interferon-alpha or interferon-alpha plus anti-vascular endothelial growth factor antibody (bevacizumab) in metastatic renal cell carcinoma

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1111/J.1464-410X.2005.05616.X

Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1111/J.1464-410X.2005.05616.X

Discovery of a novel Raf kinase inhibitor

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1111/J.1464-410X.2005.05616.X

Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal

1 reference

9 February 2024

https://opencitations.net/index/api/v1/references/10.1111/J.1464-410X.2005.05616.X

Identifiers

DOI

10.1111/J.1464-410X.2005.05616.X

1 reference

12 August 2017

1 reference